Alexion Reports Phase 1b/2 Results For ALXN1210 Show 'Rapid And Sustained Reduction Of Plasma Lactate Dehydrogenase Levels' At 8 Months, Well Tolerated, Successful Transition Of Patients To Phase 3 Dosing Regimen